...
首页> 外文期刊>Chinese journal of cancer >Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy
【24h】

Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy

机译:非小细胞肺癌根治性放疗术后局部复发的生存和预后因素

获取原文

摘要

Background Locoregional recurrence remains the challenge for long-term survival of non-small cell lung cancer (NSCLC) patients after radical surgery, and curative-intent radiotherapy could be a treatment choice. This study aimed to assess the survival and prognostic factors of patients with postoperative locoregionally recurrent NSCLC treated with radical radiotherapy. Methods We reviewed medical records of 74 NSCLC patients with postoperative locoregional recurrence who received radical radiotherapy between April 2012 and February 2016 at Sun Yat-sen University Cancer Center (Guangzhou, China). The efficacy and safety of radical radiotherapy were analyzed. The probability of survival was estimated using the Kaplan–Meier method and compared using the log-rank test. The Cox proportional hazards model was used to identify prognostic factors. Results Grade 3/4 adverse events included neutropenia (8 cases, 10.8%), esophagitis (7 cases, 9.5%), pneumonitis (1 case, 1.4%), and vomiting (1 case, 1.4%). The 2-year overall survival, progression-free survival, local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) rates of all patients were 84.2, 42.5, 70.0, and 50.9%, respectively. Univariate and multivariate analyses showed that a higher biological effective dose (BED) of radiation was associated with longer LRFS [hazard ratios (HR)?=?0.317, 95% confidence interval (CI)?=?0.112–0.899, P =?0.016] and that wild-type epidermal growth factor receptor ( EGFR ) was associated with longer DMFS compared with EGFR mutation (HR?=?0.383, 95% CI?=?0.171–0.855, P =?0.019). Conclusions Radical radiotherapy is effective and well-tolerated in NSCLC patients with postoperative locoregional recurrence. High BED is a predictor for long LRFS, and the presence of wild-type EGFR is a predictor for long DMFS.
机译:背景局部复发仍然是非小细胞肺癌(NSCLC)根治性手术后长期生存的挑战,而根治性放疗可能是一种治疗选择。这项研究旨在评估根治性放射治疗的局部复发NSCLC术后患者的生存和预后因素。方法我们回顾了2012年4月至2016年2月在中山大学肿瘤防治中心(中国广州)接受根治性放疗的74例NSCLC术后局部复发的患者的病历。分析了放射治疗的有效性和安全性。使用Kaplan-Meier方法估算生存率,并使用对数秩检验进行比较。使用Cox比例风险模型确定预后因素。结果3/4级不良事件包括中性粒细胞减少症(8例,占10.8%),食管炎(7例,占9.5%),肺炎(1例,占1.4%)和呕吐(1例,占1.4%)。所有患者的2年总生存率,无进展生存率,无局部复发生存率(LRFS)和远处无转移生存率(DMFS)分别为84.2%,42.5、70.0和50.9%。单因素和多因素分析表明,较高的放射线生物有效剂量(BED)与更长的LRFS有关[危险比(HR)?=?0.317,95%置信区间(CI)?=?0.112-0.899,P =?0.016 ],而野生型表皮生长因子受体(EGFR)与EGFR突变相比则具有更长的DMFS(HR == 0.383,95%CI == 0.171-0.855,P =?0.019)。结论根治性放疗对NSCLC术后局部复发的患者有效且耐受良好。高BED是长LRFS的预测因子,而野生型EGFR的存在是长DMFS的预测因子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号